Literature DB >> 8018952

Enzyme-linked immunosorbent assay of urokinase-type plasminogen activator (uPA) in cytosolic extracts of human breast cancer tissue.

C Rosenquist1, S M Thorpe, K Danø, J Grøndahl-Hansen.   

Abstract

The enzyme urokinase-type plasminogen activator (uPA) plays a role in cancer invasion, and high levels of uPA in detergent extracts of mammary cancer tissue have been reported to be associated with a poor prognosis. We have explored the possibility of using mammary cancer cytosol extracts routinely prepared for steroid receptor analysis for retrospective prognostic studies of uPA. A sandwich enzyme-linked immunosorbent assay (ELISA) for uPA was developed, using polyclonal catching antibodies and a mixture of three biotinylated monoclonal detecting antibodies, that were selected to recognize free uPA, inhibitor-bound uPA, and uPA bound to its cell surface receptor. The assay detects active uPA and its inactive proenzyme form, pro-uPA, equally well. The limit of detection is approximately 1 pg of pro-uPA in a volume of 100 microliters, and there is a linear dose-response up to 100 pg pro-uPA. The efficiency in extracting uPA of a neutral non-detergent buffer used to prepare cytosol extracts was compared with that of 4 other buffers. There was a pronounced difference in the efficiency, the most efficient being a pH 4.2 buffer containing the non-ionic detergent Triton X-100, while the least efficient was the buffer used to prepare cytosols. Nevertheless, uPA immunoreactivity was readily measurable in the cytosols, and there was a close correlation between the amounts of uPA extracted under optimal conditions and those routinely used for steroid hormone receptor analysis.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8018952     DOI: 10.1007/bf00666583

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  30 in total

1.  A 55,000-60,000 Mr receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification.

Authors:  L S Nielsen; G M Kellerman; N Behrendt; R Picone; K Danø; F Blasi
Journal:  J Biol Chem       Date:  1988-02-15       Impact factor: 5.157

2.  Enzyme-linked immunosorbent assay for human urokinase-type plasminogen activator and its proenzyme using a combination of monoclonal and polyclonal antibodies.

Authors:  L S Nielsen; J Grøndahl-Hansen; P A Andreasen; L Skriver; J Zeuthen; K Danø
Journal:  J Immunoassay       Date:  1986

3.  Autocrine saturation of pro-urokinase receptors on human A431 cells.

Authors:  M P Stoppelli; C Tacchetti; M V Cubellis; A Corti; V J Hearing; G Cassani; E Appella; F Blasi
Journal:  Cell       Date:  1986-06-06       Impact factor: 41.582

4.  Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer.

Authors:  M J Duffy; D Reilly; C O'Sullivan; N O'Higgins; J J Fennelly; P Andreasen
Journal:  Cancer Res       Date:  1990-11-01       Impact factor: 12.701

5.  Cellular receptor for urokinase-type plasminogen activator: protein structure.

Authors:  N Behrendt; M Ploug; E Rønne; G Høyer-Hansen; K Danø
Journal:  Methods Enzymol       Date:  1993       Impact factor: 1.600

6.  Improved medium for extraction of plasminogen activator from tissue.

Authors:  S M Camiolo; M R Siuta; J M Madeja
Journal:  Prep Biochem       Date:  1982

7.  Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor.

Authors:  E Rønne; N Behrendt; V Ellis; M Ploug; K Danø; G Høyer-Hansen
Journal:  FEBS Lett       Date:  1991-08-19       Impact factor: 4.124

8.  Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report.

Authors:  M J Duffy; P O'Grady; D Devaney; L O'Siorain; J J Fennelly; H J Lijnen
Journal:  Cancer       Date:  1988-08-01       Impact factor: 6.860

9.  Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas.

Authors:  C Pyke; P Kristensen; E Ralfkiaer; J Grøndahl-Hansen; J Eriksen; F Blasi; K Danø
Journal:  Am J Pathol       Date:  1991-05       Impact factor: 4.307

10.  Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody.

Authors:  L S Nielsen; J G Hansen; L Skriver; E L Wilson; K Kaltoft; J Zeuthen; K Danø
Journal:  Biochemistry       Date:  1982-12-07       Impact factor: 3.162

View more
  3 in total

1.  Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.

Authors:  C Holst-Hansen; B Johannessen; G Høyer-Hansen; J Rømer; V Ellis; N Brünner
Journal:  Clin Exp Metastasis       Date:  1996-05       Impact factor: 5.150

2.  Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies.

Authors:  E Rønne; G Høyer-Hansen; N Brünner; H Pedersen; F Rank; C K Osborne; G M Clark; K Danø; J Grøndahl-Hansen
Journal:  Breast Cancer Res Treat       Date:  1995-03       Impact factor: 4.872

3.  Relationship of nm23 to proteolytic factors, proliferation and motility in breast cancer tissues and cell lines.

Authors:  R L Russell; A N Pedersen; J Kantor; K Geisinger; R Long; N Zbieranski; A Townsend; B Shelton; N Brünner; T E Kute
Journal:  Br J Cancer       Date:  1998-09       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.